We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: small-cell lung cancer
MedXY News
EnglishTag

small-cell lung cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Evaluating Consolidative Thoracic Radiotherapy with Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: Insights from the Phase 2 TREASURE Trial
newsatezolizumabclinical trial

Evaluating Consolidative Thoracic Radiotherapy with Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: Insights from the Phase 2 TREASURE Trial

By MedXY|Jul 14, 2026

The Phase 2 TREASURE trial investigated the safety and efficacy of adding consolidative thoracic radiotherapy to atezolizumab maintenance in extensive-stage small cell lung cancer, revealing increased toxicity without survival benefit, unde

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial
Hematology-Oncology
first-line treatment
immunotherapy

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

By MedXY|Jun 7, 2026

Extended follow-up from ASTRUM-005 shows serplulimab plus chemotherapy improves long-term survival in untreated extensive-stage small cell lung cancer, with manageable safety and encouraging patient-reported outcomes.

Checkpoint inhibition for frail patients: Durvalumab with carboplatin–etoposide shows tolerability and a 1‑year survival signal in poor‑performance‑status extensive‑stage SCLC (NEJ045A)
newsdurvalumabsmall-cell lung cancer

Checkpoint inhibition for frail patients: Durvalumab with carboplatin–etoposide shows tolerability and a 1‑year survival signal in poor‑performance‑status extensive‑stage SCLC (NEJ045A)

By MedXY|Dec 1, 2025

NEJ045A shows durvalumab plus carboplatin–etoposide is feasible in ES‑SCLC patients with PS2–3, with induction completion rates above thresholds and a 1‑year survival of 43.4% overall, supporting cautious use of chemo‑immunotherapy in selec

Safety and Activity of Tarlatamab Combined with PD-L1 Inhibitors as First-Line Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer: Insights from the DeLLphi-303 Phase 1b Study
Oncologymaintenance therapysmall-cell lung cancer

Safety and Activity of Tarlatamab Combined with PD-L1 Inhibitors as First-Line Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer: Insights from the DeLLphi-303 Phase 1b Study

By MedXY|Oct 15, 2025

This review synthesizes evidence on tarlatamab plus PD-L1 inhibitors as maintenance therapy post chemo-immunotherapy in extensive-stage SCLC, highlighting safety, clinical activity, and translational implications from the DeLLphi-303 study

Expanding the Role of Stereotactic Radiosurgery in Small Cell Lung Cancer with Brain Metastases: Insights from a Prospective Multicenter Phase II Trial
Clinical UpdatesBrain MetastasesPhase II Trial

Expanding the Role of Stereotactic Radiosurgery in Small Cell Lung Cancer with Brain Metastases: Insights from a Prospective Multicenter Phase II Trial

By MedXY|Oct 8, 2025

A prospective phase II trial shows stereotactic radiosurgery offers a low neurologic death rate in SCLC patients with 1-10 brain metastases, challenging the traditional favoring of whole-brain radiation therapy.

Obrixtamig (BI 764532): A Promising DLL3/CD3 T-Cell Engager in Heavily Pretreated DLL3-Positive Neuroendocrine Cancers
newsDLL3Obrixtamig

Obrixtamig (BI 764532): A Promising DLL3/CD3 T-Cell Engager in Heavily Pretreated DLL3-Positive Neuroendocrine Cancers

By MedXY|Oct 8, 2025

Phase I trial of obrixtamig, a DLL3/CD3 T-cell engager, shows tolerability and encouraging efficacy in heavily pretreated patients with DLL3-positive SCLC and neuroendocrine carcinomas, supporting further development.

Optimizing Twice-Daily Thoracic Radiotherapy Dosage in Limited-Stage Small-Cell Lung Cancer: Impact on Survival and Toxicity
Clinical Updateschemoradiotherapysmall-cell lung cancer

Optimizing Twice-Daily Thoracic Radiotherapy Dosage in Limited-Stage Small-Cell Lung Cancer: Impact on Survival and Toxicity

By MedXY|Oct 5, 2025

A phase II trial reveals that high-dose twice-daily thoracic radiotherapy (60 Gy/40 fractions) significantly improves survival without increasing severe toxicity compared to the standard dose (45 Gy/30 fractions) in limited-stage SCLC patie

First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial
Clinical Updatesatezolizumabimmunotherapy

First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial

By MedXY|Oct 1, 2025

The IMforte phase 3 trial demonstrates that lurbinectedin plus atezolizumab as first-line maintenance significantly prolongs progression-free and overall survival in extensive-stage small-cell lung cancer, albeit with increased hematologic

Tarlatamab versus Chemotherapy in Relapsed Small-Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial
Clinical Updatesimmunotherapyphase 3 trial

Tarlatamab versus Chemotherapy in Relapsed Small-Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial

By MedXY|Sep 30, 2025

Tarlatamab significantly improves overall survival and reduces severe adverse events compared to chemotherapy in patients with small-cell lung cancer progressing after platinum-based therapy.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities